



Preclinical Platform of Disease-modifying Prodrugs
to Durably Reverse the Course of Chronic Inflammatory Diseases (CIDs)

Initial indications: Periodontitis, IBD


April 10, 2026

Copyright © 2025- HypO2Regen Therapeutics, Inc. - do not reproduce without authorization

Conjugates of a known antifibrotic small molecules to versatile biopolymer carrier

- HO2RT- novel proprietary platform of Small Molecule Drug Conjugate (SMDC) prodrugs

- Known antifibrotic
- Tight target selectivity
- No significant *in vivo* toxicities
- 5 approved drugs in class



JUST 2 low-dose SQ inj. —————→ **Durable clinical benefit**

- Potential regulatory upside: PRIME in Europe, Fast-Track in the US, NCE eligibility

3-Fold Problem of Current Chronic Inflammation Treatments HO_2R_x

Current
Standard
of
Care

NO Functional Tissue Healing

- **Fibrotic scarring prevents functional restoration**, permanent organ impairment
- 70% Crohn's Disease pts require **surgery**
- Implants and grafts have **no healing effect** and can lead to periimplantitis

High-toxicity Not durable

- **Black box warning**-most prescribed IBD drugs causing poor compliance, more frequent/severe relapses, disease progression
- **Drug resistance, pain, poor QoL**
- **Disease progression** - increasingly frequent, severe relapses

Expensive

Life-long
Yearly, repeat
6-figure treatment

HO_2RT
drugs

Functional Tissue Healing

- **Scarless tissue restoration:** structure + function
- **Mimics natural tissue**
- **Disease-modifying:** reversion of tissue damage

Low Toxicity Durable Effect

- **Retains proven benefits of RSCTs** (Regenerative Stem Cell Therapies)
- **Halts remission-relapse cycles and disease progression**
- **Reverses disease course**

Affordable

- **Lower treatment costs**
- **Better reimbursement**
- **High adoption:** clinicians, patients


Solution: Game-changing Therapeutic Concept




DRUG Treatment Mimics Natural Tissue Healing Processes

Pioneering Stem Cell Therapy
WITHOUT cell manipulations
outside the body (“*ex vivo*”)

- Retains the proven benefits of Stem Cell Therapies (SCT), *but* WITHOUT risky, costly cell manipulations
- Simple, Easy administration: NO multiple patient visits to specialty cell therapy centers, specialty care



HO2RT Platform: Differentiated Products Opportunities




Periodontitis: Low-cost Access to Huge CID Market




\$10M investment • under \$50M Total Dev. Costs • \$30B peak revenues*

- **Neglected disease** - 70% under-treated (> 160M US/EUR), ineffective, >\$100k/Y, invasive, painful treatments
- **Early efficacy read in dog** - pilot study to confirm efficacy seen in rodents, derisks human clinical development
- **Dog pilot study monetized by out-licensed** veterinary product development (**HO2RT201**), veterinary blockbuster likely to fund 50-75% human periodontitis drug development (**HO2RT-101**)




**Management estimates, calculations available in data room*

Therapeutic concept translates into real, durable regeneration of soft and hard tissues



Just 2 subQ
8 days apart




Severe periodontitis rodent model (“LIP”): 10-day ligature around molar causes severe microbiome dysbiosis, leading to destructive inflammation of the alveolar bone + soft tissues, replicating severe human periodontitis.



Significant vertical + horizontal regeneration
Quasi complete restoration of alveolar bone + soft tissue, 100% tooth reattachment, + pulp activation. Confirmed by histology.




Scarless healing of the intestinal mucosa after only 1 low-dose injection of HO2RT-101



Drug-targeted pathway activation correlates with structural restoration of previously destroyed microvilli of the intestinal mucosa, without evidence of fibrotic scarring




Competitive Positioning: Game-changing Therapy



* Only in humans

TAM, SAM, SOM – Human Periodontitis (US+EUR)



** Management estimates- calculations available in data room*

Team – Synergistic Expertise, Innovative Minds



Co-founders



Dr. Isabelle Gorrillot
Co-founder & CEO

30Y Biotech growth, BDL



Prof. Phillip Messersmith
Co-founder

Chair, BioEngineering

UC Berkeley

Clinical Advisors



Thomas W Campi, DVM, MVPM
CEO, Modulant BioSci,
Former Head of BDL, Elanco



Jean-Marc Dersot, DDS, PhD
Periodontist Consultant



Corporate Advisors



Michael Tippie
General partner

Alignment Ventures, LLC



Bruce Kaufman
Managing Director,
Healthcare Group



- **Versatile Prodrug Platform** tackles the growing **>\$100B Chronic Inflammatory Disease (CID)** market
- **Initial indication: Periodontitis** - “**low-hanging fruit**” in the **CID market** – grossly neglected disease, yet easy and fast development requiring less than \$50M to fund the entire clinical development of HO2RT-101
- **BUT.... only \$10M investment needed** - because royalty income on sales of HO2RT-201 (pet periodontitis) starting in 2030 (estimated \$11-50M⁺/Y)
- **Innovative therapy drug-induced (*in vivo*) stem cell therapy mimics** natural **scarless** healing ensuring normal tissue integrity, **AND translates into strong efficacy** (periodontitis, IBD rodent models); positive signals in liver, kidney, and multiple skin injuries
- **Broad pipeline expansion avenues** (e.g., CVD, NAFLD, IBD) and **additional out-licensing revenue streams** (wound healing, burns Medtech/Veterinary)

Contact: Isabelle Gorrillot, CEO – isabelleg@ho2rx.com